EUVIMEDEUVIMED entdecken
Crossref

Pembrolizumab (Keytruda)

CDA-AMC

Canadian Journal of Health Technologies · 13.03.2026 · 6 (3)

DOI: 10.51731/cjht.2026.1382 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Journal of Health Technologies, online erschienen am 13.03.2026. Verfasst von CDA-AMC.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses pembrolizumab (Keytruda), 100 mg/4 mL vial, solution for infusion. Indication: For the treatment of adult patients with HNSCC whose tumours express PD-L1 (CPS ≥ 1), as determined by a validated test, as neoadjuvant treatment as monotherapy, continued as adjuvant treatment in combination with RT with or without cisplatin and then as monotherapy.

Zitieren

APA

CDA-AMC (2026). Pembrolizumab (Keytruda). Canadian Journal of Health Technologies, 6(3). https://doi.org/10.51731/cjht.2026.1382

Vancouver

CDA-AMC. Pembrolizumab (Keytruda). Canadian Journal of Health Technologies. 2026;6(3). doi:10.51731/cjht.2026.1382

BibTeX
@article{CDAAMC2026,
  author = {CDA-AMC},
  title = {Pembrolizumab (Keytruda)},
  journal = {Canadian Journal of Health Technologies},
  year = {2026},
  volume = {6},
  number = {3},
  doi = {10.51731/cjht.2026.1382}
}
Kostenlos starten →